Compare AFBI & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFBI | SLGL |
|---|---|---|
| Founded | 1928 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.3M | 247.1M |
| IPO Year | 2020 | 2016 |
| Metric | AFBI | SLGL |
|---|---|---|
| Price | $19.24 | $75.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | 2.5K | ★ 10.4K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.05 | $0.40 |
| 52 Week High | $22.25 | $97.97 |
| Indicator | AFBI | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 38.22 | 48.25 |
| Support Level | $18.60 | $71.01 |
| Resistance Level | $19.85 | $97.97 |
| Average True Range (ATR) | 0.31 | 11.22 |
| MACD | -0.12 | -2.09 |
| Stochastic Oscillator | 26.25 | 25.96 |
Affinity Bancshares Inc is a holding company of Affinity Bank, a federally chartered stock savings bank that offers a variety of deposit accounts, including checking accounts, savings accounts, and certificate of deposit accounts. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate loans, commercial and industrial loans, residential real estate loans, construction and land loans, and consumer loans. It also invests in securities, which consist of mortgage-backed securities and obligations issued by United States government-sponsored enterprises and Federal Home Loan Bank stock.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.